Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666411 | 1.00 | KDM4E (0.46) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| SCHEMBL30100747 | 1.00 | KDM4E (0.46) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL10524097 | 0.98 | KDM4E (0.45) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| Formaldehyde SCHEMBL27640099 | 0.94 | KDM4E (0.42) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| Biphenyl SCHEMBL28365892 | 0.92 | NPC1 (0.44) | KDM4EEGFRGPR3ALDH1A1GLA | |
| SCHEMBL20163588 | 0.88 | EGFR (0.38) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| SCHEMBL29520469 | 0.80 | CYP1A2 (0.44) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| Valine SCHEMBL9998032 | 0.76 | SLC7A5 (0.42) | KDM4EALDH1A1CYP1A2SMN1; SMN2RAB9A | |
| SCHEMBL30198446 | 0.75 | CYP1A2 (0.60) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| SCHEMBL30527184 | 0.75 | CYP1A2 (0.60) | KDM4EEGFRGPR3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486809-A | 2-chloroquinazoline compound, preparation method and application thereof in preparation of medicines for preventing or treating breast cancer | 浙江工业大学 | 2024-02-02 | — | — | CN | claimed |
| CN-114920704-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | claimed |
| CN-114886896-B | Application of 2-chloroquinazoline derivative or pharmaceutically acceptable salt thereof in preparation of medicines for preventing or treating cervical cancer | 浙江工业大学 | 2023-07-14 | — | — | CN | claimed |
| CN-114920704-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-08-19 | — | — | CN | claimed |
| CN-114886896-A | Application of 2-chloroquinazoline derivative or pharmaceutically acceptable salt thereof in preparation of drugs for preventing or treating cervical cancer | 浙江工业大学 | 2022-08-12 | — | — | CN | claimed |
| CN-112300082-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-04-26 | — | — | CN | claimed |
| WO-2021017996-A1 | PHENYLPIPERAZINE QUINAZOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 暨南大学 | 2021-02-04 | — | — | WO | claimed |
| CN-112300082-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2021-02-02 | — | — | CN | claimed |
| CN-105520951-B | The polysaccharid derivative of toroidal shell containing quinazoline and preparation method and bioactivity | 鲁东大学 | 2018-09-18 | — | — | CN | claimed |
| CN-104230826-B | 2 fluoro quinazoline cyclics and preparation method thereof and pharmaceutical usage | 复旦大学 | 2017-03-29 | — | — | CN | claimed |
| US-20150141421-A1 | 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS | NATCO PHARMA LIMITED (IN) | 2015-05-21 | — | — | US | claimed |
| CN-102702178-B | Process for the preparation of lapatinib and the salts thereof | ITALIANA SINT SPA | 2015-03-04 | — | — | CN | claimed |
| US-20110034459-A1 | 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS | NATCO PHARMA LTD. (IN) | 2011-02-10 | — | — | US | claimed |
| EP-0954315-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | Sugen, Inc. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998010767-A9 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | — | 1998-07-02 | — | — | WO | claimed |
| WO-1998010767-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | SUGEN, INC. (US) | 1998-03-19 | — | — | WO | claimed |
| CN-121248582-B | CDK12/PARP double-target inhibitor and preparation method and application thereof | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260137684-A1 | ROCK2 Inhibitors And Uses Thereof | RESTOR PHARMACEUTICALS (US) | 2026-05-21 | — | — | US | disclosed |
| US-4133955-A | Process for the production of 2-equivalent yellow couplers | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1979-01-09 | — | — | US | disclosed |
| US-4098788-A | Process for preparing quinazolines | BRISTOL-MYERS COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034459-A1 | 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS | ERBB2, EGFR, ERBB3 | KDM4E 2923/4885EGFR 2/4885GPR3 156/4885 |
| US-20150141421-A1 | 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS | ERBB2, EGFR, GRK3 | KDM4E 3005/4885EGFR 2/4885GPR3 92/4885 |
| US-20260137684-A1 | ROCK2 Inhibitors And Uses Thereof | ROCK2, ROCK1, RHOA | KDM4E 1974/4885EGFR 1956/4885GPR3 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.